Cerebrolysin in childhood autism: clinical and EEG findings
L. S. Chutko, E. A. Yakovenko, S. Yu. Surushkina, E. M. Kryukova, S. V. Palaieva · 2017 · Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):71–75. PMID 29053124.
Reported findings and study design
Uncontrolled before–after study of 43 children. The authors compared two clinical subgroups defined using their historical classification. All children received Cerebrolysin.
Dose, route and schedule
Fifteen intramuscular injections of 2.0 mL each, given every other day. The article reports no other therapy during that period. CARS was measured at baseline and on days 30 and 60. EEG was repeated at day 60.
Protocol source ↗ · Original Russian article, methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Signs of improvement at end of course | 27/43 (62.8%) improved; 16/43 (37.2%) had no positive change | Day 30 |
| Improvement by subgroup | 13/23 (56.5%) in the “endogenous” group and 14/20 (70.0%) in the “organic” group | Parent reports; both groups received Cerebrolysin. |
| Increased hyperactivity | 16/43 during treatment and 10/43 (23.3%) at day 60 | The paper prints 37.8% for the first count; 16/43 is 37.2%. |
| CARS and EEG at follow-up | CARS decreased in both subgroups. The authors reported regional alpha and theta changes and no newly detected epileptiform activity. | Day 60 |
An uncontrolled study cannot separate treatment effects from time, expectation, or measurement. The EEG observation applies only to this selected sample, which excluded children with epilepsy.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Both subgroups received Cerebrolysin. Baseline CARS scores differed and there was no untreated or placebo group.
- Parent observations and EEG changes cannot establish an autism treatment effect. Exclusion of children with epilepsy limits safety interpretation.
Source access
Original publisher text checked for clinical outcomes, EEG methods and adverse effects. The numerical CARS table image could not be verified.
Source reviewed 2026-11-10.
Source type: Original clinical journal article
Citation and original source
Original source: L. S. Chutko, E. A. Yakovenko, S. Yu. Surushkina, E. M. Kryukova, S. V. Palaieva. Cerebrolysin in childhood autism: clinical and EEG findings Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):71–75. PMID 29053124. 2017.
Molekul research summary: https://molekul.io/research/cerebrolysin-chutko-autism-2017. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry